HAGEN Cramer

Company: QurAlis

Job title: Chief Technology Officer

Bio:

Dr. Hagen Cramer is a renowned expert in all chemistry-related aspects of oligonucleotide therapeutic development. He has worked in the biotech industry for over 25 years spanning discovery, development and manufacturing of oligonucleotide-based therapeutics. Early in his career he worked with Gemini Technologies and Ridgway Biosystems on the discovery of 2-5A antisense for the treatment of a variety of cancers and viral diseases. In 2005 he joined Girindus, which was later acquired by Nitto Denko Avecia where he headed the process development department, eventually becoming Director of Operations. More recently he joined Wave Life Sciences where he was responsible for securing drug substance and drug product for its clinical pipeline of stereodefined oligonucleotide therapeutics. In 2020 he joined QurAlis as Chief Technology Officer supporting all programs targeting diseases affecting the CNS.

Seminars:

Navigating CMC Complexity: Overcoming Manufacturing & Cost Barriers to Advance Next-Generation Oligonucleotide Therapeutics 2:00 pm

Why multi-component designs present unique manufacturing and regulatory hurdles to understand the CMC burden of novel oligos New approaches to reduce cost and complexity: Including, enzymatic ligation, and emerging scalable manufacturing technologies Building global manufacturing readiness: Evaluating current capacity and capabilities to meet growing demand for large-scale, GMP-compliant oligonucleotide productionRead more

day: Conference Day Two

Panel Discussion: Turning Setbacks into Strategy, what Clinical Trial Failures Teach us About Building Better Oligonucleotide Therapies 9:00 am

Unpack the reasons behind trial discontinuations: Was it the oligo, delivery system, or something else? Identify overlooked red flags in preclinical models, PK data, or target biology that led to setbacks Discuss how teams rebounded, what pivots, partnerships, or reformulations turned failure into future successRead more

day: Conference Day One